Apotea AB (publ) (STO:APOTEA)
72.15
0.00 (0.00%)
Aug 12, 2026, 10:18 AM CET
Apotea AB Revenue
Apotea AB had revenue of 2.03B SEK in the quarter ending June 30, 2026, with 10.94% growth. This brings the company's revenue in the last twelve months to 7.59B, up 9.38% year-over-year. In the year 2025, Apotea AB had annual revenue of 7.21B with 10.15% growth.
Revenue (ttm)
7.59B
Revenue Growth
+9.38%
P/S Ratio
0.99
Revenue / Employee
10.31M
Employees
736
Market Cap
7.51B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 7.21B | 663.90M | 10.15% |
| Dec 31, 2024 | 6.54B | 1.09B | 19.91% |
| Dec 31, 2023 | 5.46B | 572.40M | 11.72% |
| Dec 31, 2022 | 4.88B | 303.30M | 6.62% |
| Dec 31, 2021 | 4.58B | 1.74B | 61.34% |
| Dec 1, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 1, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 1, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 1, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 1, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Getinge AB | 34.24B |
| Swedish Orphan Biovitrum AB | 30.62B |
| Arjo AB | 10.92B |
| Synsam AB | 7.13B |
| Sectra AB | 3.65B |
| Dynavox Group AB | 2.54B |
| Camurus AB | 2.27B |
| MedCap AB | 2.26B |
Apotea AB News
- 26 days ago - Apotea AB Earnings Call Transcript: Q2 2026 - Transcripts
- 26 days ago - Apotea AB Quarterly report: Q2 2026 - Filings
- 26 days ago - Apotea AB Slides: Q2 2026 - Filings
- 3 months ago - Apotea AB Earnings Call Transcript: Q1 2026 - Transcripts
- 3 months ago - Apotea AB Quarterly report: Q1 2026 - Filings
- 3 months ago - Apotea AB Slides: Q1 2026 - Filings
- 6 months ago - Apotea AB Earnings Call Transcript: Q4 2025 - Transcripts
- 6 months ago - Apotea AB Quarterly report: Q4 2025 - Filings